wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q39220897-49F9FCE2-A21E-49A3-B9C7-55C40C774CFE
Q39220897-49F9FCE2-A21E-49A3-B9C7-55C40C774CFE
BestRank
Statement
http://www.wikidata.org/entity/statement/Q39220897-49F9FCE2-A21E-49A3-B9C7-55C40C774CFE
Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer.
P2860
Q39220897-49F9FCE2-A21E-49A3-B9C7-55C40C774CFE
BestRank
Statement
http://www.wikidata.org/entity/statement/Q39220897-49F9FCE2-A21E-49A3-B9C7-55C40C774CFE
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
1875fae4b6b352323e8ba5030e04aee2738d464e
P2860
A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib.